First in human study with a prodrug of galantamine: Improved benefit-risk ratio?

INTRODUCTION: Gln-1062 (Memogain) is a pharmacologically inactive prodrug of galantamine. Owing to its lipophilic nature, it preferentially enters the brain, where it is cleaved into active galantamine. Gln-1062 is expected to have fewer peripheral side effects than other cholinesterase inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Baakman, Anne C., 't Hart, Ellen, Kay, Denis G., Stevens, Jasper, Klaassen, Erica S., Maelicke, Alfred, Groeneveld, Geert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644278/
https://www.ncbi.nlm.nih.gov/pubmed/29067291
http://dx.doi.org/10.1016/j.trci.2015.12.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644278/
https://www.ncbi.nlm.nih.gov/pubmed/29067291
http://dx.doi.org/10.1016/j.trci.2015.12.003

Ejemplares similares